BAC
Bank of America Corporation
BAC has the edge over HBCP overall, supported by stronger fundamentals and stronger valuation.
HBCP
Home Bancorp, Inc.
HBCP trails on the overall score without a compensating advantage in the available component scores.
BAC Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
BAC's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like BAC.
HBCP Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| N/A | |
| N/A |
HBCP's profitability is currently healthy, and its revenue is stable. Free cash flow and net leverage aren't meaningful measures for financial services companies like HBCP.
BAC PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 9.4x | $39.50 | -22% |
| Forward | 10x | $50.51 | — |
| Current | 12x | $50.51 | — |
| Fair | 13x | $53.81 | +6.5% |
| Expensive | 15x | $62.23 | +23% |
Historical ranges are pointers, not guarantees.
BAC has the edge over HBCP in the historical PE scenario, which offers more potential upside but is not a forecast.
HBCP PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 7.2x | $40.80 | -34% |
| Fair | 9.8x | $55.58 | -9.8% |
| Forward | 10x | $61.62 | — |
| Expensive | 11x | $64.91 | +5.3% |
| Current | 11x | $61.62 | — |
Historical ranges are pointers, not guarantees.
HBCP's PE is in its expensive range at 11x. On analysts' estimates for next year's earnings, today's price would be 10x, in its fair range.
BAC Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Moderate |
BAC has the edge over HBCP on the outlook, with more favorable valuation and earnings expectations.
HBCP Forward outlook
| Metric | Outlook |
|---|---|
| Stable | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| High |
Analysts expect HBCP's revenue to grow, but its profitability to weaken.
BAC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $4.92 | +17% |
| Q3 2026 | $4.19 | +14% |
| Q2 2026 | $4.34 | +27% |
| Q1 2026 | $4.02 | +20% |
| Q4 2025 | $3.81 | +19% |
| Q3 2025 | $3.66 | +33% |
| Q2 2025 | $3.41 | +20% |
| Q1 2025 | $3.35 | +16% |
| Q4 2024 | $3.21 | +4.2% |
BAC has the edge over HBCP on earnings, with more consistent year-over-year improvement.
HBCP Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $5.92 | +4.4% |
| Q3 2026 | $5.67 | +0.9% |
| Q2 2026 | $5.98 | +15% |
| Q1 2026 | $5.95 | +24% |
| Q4 2025 | $5.87 | +29% |
| Q3 2025 | $5.62 | +25% |
| Q2 2025 | $5.21 | +15% |
| Q1 2025 | $4.78 | +0.8% |
| Q4 2024 | $4.55 | -8.8% |
HBCP earned $5.67 per share over the past year, about the same as the year before.
BAC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $30B | +6.7% |
| Q2 2026 | $31.6B | +19% |
| Q1 2026 | $30.3B | +11% |
| Q4 2025 | $31.2B | +23% |
| Q3 2025 | $28.1B | +11% |
| Q2 2025 | $26.5B | +4.3% |
| Q1 2025 | $27.4B | +6% |
| Q4 2024 | $25.3B | +15% |
BAC has the edge over HBCP on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 30% | -3.7 points |
| Q2 2026 | 37% | +7.6 points |
| Q1 2026 | 34% | +4.7 points |
| Q4 2025 | 40% | +12 points |
| Q3 2025 | 34% | +4.8 points |
| Q2 2025 | 29% | -0.7 points |
| Q1 2025 | 30% | +1.5 points |
| Q4 2024 | 28% | +14 points |
BAC's operating margin was 30% last quarter, down 3.7 points from the same quarter a year ago.
HBCP Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $40.1M | +6% |
| Q2 2026 | $39.7M | +7.2% |
| Q1 2026 | $38.2M | +6.9% |
| Q4 2025 | $38M | +8% |
| Q3 2025 | $37.8M | +11% |
| Q2 2025 | $37.1M | +12% |
| Q1 2025 | $35.8M | +10% |
| Q4 2024 | $35.2M | +7.5% |
HBCP's revenue has grown year over year for nine quarters in a row: $40M last quarter, up 6% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 32% | -9.2 points |
| Q2 2026 | 36% | -2 points |
| Q1 2026 | 38% | -1 points |
| Q4 2025 | 38% | +4.1 points |
| Q3 2025 | 41% | +6.8 points |
| Q2 2025 | 38% | +7.8 points |
| Q1 2025 | 39% | +3.3 points |
| Q4 2024 | 34% | -1 points |
HBCP has the edge over BAC on profitability, with a higher operating margin.
BAC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$6.5B | -114% |
| Q2 2026 | $29B | +$38.2B |
| Q1 2026 | $41.8B | +$44B |
| Q4 2025 | -$22.9B | -189% |
| Q3 2025 | $46.9B | +$84.2B |
| Q2 2025 | -$9.1B | -150% |
| Q1 2025 | -$2.2B | +$13.4B |
| Q4 2024 | $25.9B | -21% |
BAC's free cash flow was $41.4B over the past year, down 33% from the year before. Free cash flow isn't a meaningful measure for financial services companies like BAC.
HBCP Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $23.5M | +14% |
| Q2 2026 | $9.3M | +18% |
| Q1 2026 | $14.5M | +66% |
| Q4 2025 | $7.1M | +34% |
| Q3 2025 | $20.7M | +22% |
| Q2 2025 | $7.9M | -41% |
| Q1 2025 | $8.7M | -4.1% |
| Q4 2024 | $5.3M | -45% |
HBCP has the edge over BAC on cash flow, with more consistent year-over-year improvement.
BAC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1% | -72M shares |
| 1 year | -5.3% | -405M shares |
| 3 years | -11% | -854M shares |
| 5 years | -15% | -1.3B shares |
| Available history | -24% | -2.2B shares |
BAC has the edge over HBCP on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $6B |
| Q2 2026 | $6B |
| Q1 2026 | $7.2B |
| Q4 2025 | $6.3B |
| Q3 2025 | $5.3B |
| Q2 2025 | $5.3B |
| Q1 2025 | $4.5B |
| Q4 2024 | $3.5B |
BAC spent $25.6B buying back its own shares over the past year, up 37% from the year before.
HBCP Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.3% | +21K shares |
| 1 year | +1.2% | +91K shares |
| 3 years | -2.1% | -165K shares |
| 5 years | -6.3% | -532K shares |
| Available history | -14% | -1.3M shares |
HBCP has 8M diluted shares, up 1.2% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $25,000 |
| Q2 2026 | $182,000 |
| Q1 2026 | $249,000 |
| Q4 2025 | $42,000 |
| Q3 2025 | $5,000 |
| Q2 2025 | $6.5M |
| Q1 2025 | $7.8M |
| Q4 2024 | $88,000 |
HBCP spent $498,000 buying back its own shares over the past year, down 97% from the year before.
BAC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 6.4x | High |
| Q2 2026 | 6.7x | High |
| Q1 2026 | 7.1x | High |
| Q4 2025 | 7.7x | High |
| Q3 2025 | 8.3x | High |
| Q2 2025 | 8.8x | High |
| Q1 2025 | 8.6x | High |
| Q4 2024 | 9.0x | High |
BAC's net debt is about 6.4 years of its operating earnings (EBITDA), down from 8.3 years a year ago. Net leverage isn't a meaningful measure for financial services companies like BAC.
HBCP Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -2.1x | Net Cash |
| Q2 2026 | -2.1x | Net Cash |
| Q1 2026 | -2.7x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -0.9x | Net Cash |
| Q1 2025 | -1.0x | Net Cash |
| Q4 2024 | -0.8x | Net Cash |
HBCP has the edge over BAC on leverage, with a lower net debt burden relative to earnings.
BAC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.1 | Neutral |
| Stochastic | 4.9 | Oversold |
BAC's weekly RSI is 37 (neutral) and its Stochastic is 5 (oversold).
HBCP Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 38.1 | Neutral |
| Stochastic | 23.4 | Neutral |
HBCP's weekly RSI is 38 (neutral) and its Stochastic is 23 (neutral).
BAC PE vs Financial Services Sector
| Metric | BAC | Sector median | Relative |
|---|---|---|---|
| PE | 12x | 13x | 7.5% below |
| PE % | 40 | 63 | 23 pts below |
BAC is trading at 12x earnings, in line with the Financial Services sector's median of 13x.
HBCP PE vs Financial Services Sector
| Metric | HBCP | Sector median | Relative |
|---|---|---|---|
| PE | 11x | 13x | 17% below |
| PE % | 76 | 63 | 13 pts above |
HBCP has the edge over BAC on valuation relative to its sector.
BAC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $52.1 | 3% below |
| 20 week MA | $57.8 | 13% below |
| 50 week MA | $54.7 | 7.7% below |
| 100 week MA | $50.5 | 0% below |
| 200 week MA | $42.5 | 19% above |
BAC has fallen below most of its moving averages, though it's still 19% above its 200-week average.
HBCP Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $63.9 | 3.6% below |
| 20 week MA | $67.5 | 8.8% below |
| 50 week MA | $64.2 | 4% below |
| 100 week MA | $57.4 | 7.4% above |
| 200 week MA | $47.7 | 29% above |
HBCP has the edge over BAC on trend strength, trading above more of its moving averages.
BAC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $35.4 | $30.0 | -15% |
| 2021 | $30.0 | $44.4 | +48% |
| 2022 | $44.4 | $32.5 | -27% |
| 2023 | $32.5 | $33.7 | +3.7% |
| 2024 | $33.7 | $44.3 | +32% |
| 2025 | $44.3 | $56.2 | +27% |
| 2026 YTD | $56.2 | $50.5 | -10% |
BAC has finished higher in four of the last six years. It's down 10% so far in 2026.
HBCP Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $38.8 | $28.8 | -26% |
| 2021 | $28.8 | $41.9 | +46% |
| 2022 | $41.9 | $40.8 | -2.5% |
| 2023 | $40.8 | $42.0 | +3% |
| 2024 | $42.0 | $46.1 | +9.8% |
| 2025 | $46.1 | $59.4 | +29% |
| 2026 YTD | $59.4 | $61.6 | +3.8% |
HBCP has the edge over BAC on returns for 2026, with the stronger performance.